Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Stromal Tumors 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Pemetrexed 23Cisplatin 19Nivolumab 8Gemcitabine 7Ipilimumab 6Carboplatin 6pembrolizumab 4Bevacizumab 4tazemetostat 3durvalumab 3Fluorouracil 3Drug Therapy 3spartalizumab 2olaparib 2niraparib 2budigalimab 2belinostat 2anetumab ravtansine 2amatuximab 2Vinorelbine 2Radiotherapy, Intensity-Modulated 2Paclitaxel 2PM 01183 2Oxaliplatin 2Imatinib Mesylate 2Everolimus 2Erlotinib Hydrochloride 2Doxorubicin 2Cyclophosphamide 2venetoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Mesothelioma × OSI 930 × Clear all
NCT00603356 2011-09-27

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Astellas Pharma Inc

Phase 1 Completed
60 enrolled
GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Neoplasms, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡